From Evidence to Practice: Denosumab in Osteoporosis and Joint Health

Osteoporosis and osteopenia are prevalent conditions in India, particularly among postmenopausal women and the elderly,leading to increased fracture risks and morbidity. Denosumab, a monoclonal antibody, demonstrates superior efficacyover other treatments in reducing fracture risk and enhancing bone mineral density (BMD). Clinical trials highlight itseffectiveness in preventing periprosthetic bone loss, improving implant stability, and mitigating femoral head collapse invarious conditions; combination therapies involving denosumab further amplify BMD gains and reduce fracture risk. Thearticle reviews the efficacy and safety of denosumab in managing osteoporosis, joint replacement therapy, and avascularnecrosis based on a review of clinical evidence and studies. Denosumab emerges as a cornerstone therapy for osteoporosismanagement, offering multifaceted benefits in fracture prevention, joint replacement therapy, and avascular necrosis.

• Publication year

  2024

• Venue

  Indian Journal Of Clinical Practice

• Publication date

  2024-05-24

• Fields of study

  Not labeled

• Identifiers
  DOI 10.59793/ijcp.v34i12.996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy

  2022cited by this paper
• Prevalence and Predictors of Osteoporosis and Osteopenia in Postmenopausal Women of Punjab, India

  2022influential reference
• Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

  2021cited by this paper
• Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review

  2021cited by this paper
• Prevalence of osteoporosis in India: an observation of 31238 adults

  2021influential reference
• Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial.

  2021cited by this paper
• Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty.

  2020cited by this paper
• Reply to Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".

  2020cited by this paper
• Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial

  2020cited by this paper
• Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use.

  2019influential reference
• Rates and Risk Factors for Revision Hip Arthroscopy.

  2019cited by this paper
• Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty

  2019cited by this paper
• Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty

  2018cited by this paper
• One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

  2018cited by this paper
• Prevalence of osteoporosis and osteopenia in an apparently healthy Indian population - a cross-sectional retrospective study

  2018cited by this paper
• FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

  2018cited by this paper
• Denosumab reduces early migration in total knee replacement

  2017cited by this paper
• Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

  2015cited by this paper
• Response to Denosumab Treatment for 2 Years in an Adolescent With Osteoradionecrosis

  2015cited by this paper
• Denosumab for the treatment of osteoporosis

  2015cited by this paper
• Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension

  2014cited by this paper
• Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.

  2014cited by this paper
• Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

  2013influential reference
• A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

  2012cited by this paper
• Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

  2011cited by this paper
• Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

  2011influential reference
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

  2010influential reference
• Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

  2009cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008cited by this paper
• Freedom

  1890cited by this paper

• No citing papers are available for this paper.